Which medication is administered via IV infusion every 4 weeks?

Natalizumab, marketed as Tysabri, is a monoclonal antibody medication used in the treatment of multiple sclerosis (MS). It is specifically designed for patients with relapsing forms of MS who have had an inadequate response to other therapies. The key feature of this medication is its administration schedule, which involves an intravenous infusion typically every four weeks. This is significant because the dosing schedule can impact adherence and overall treatment management for patients.

Natalizumab works by binding to the alpha-4 subunit of integrins, which inhibits the migration of lymphocytes into the central nervous system, thereby reducing inflammation and the frequency of relapses. Its efficacy in treating MS has made it a crucial option for many patients, particularly those who may not respond to other treatments.

Understanding the route of administration and dosing frequency is essential for effective patient management, especially in chronic conditions like MS where medication adherence can significantly influence patient outcomes.